KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Abbott Laboratories (ABT) Receivables - Net (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Receivables - Net for 17 consecutive years, with $7.9 billion as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 14.5% to $7.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.9 billion through Dec 2025, up 14.5% year-over-year, with the annual reading at $7.9 billion for FY2025, 14.5% up from the prior year.
  • Receivables - Net hit $7.9 billion in Q4 2025 for Abbott Laboratories, down from $8.1 billion in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $8.1 billion in Q3 2025 to a low of $6.0 billion in Q1 2023.
  • Historically, Receivables - Net has averaged $6.8 billion across 5 years, with a median of $6.6 billion in 2023.
  • Biggest five-year swings in Receivables - Net: grew 18.93% in 2021 and later dropped 16.14% in 2023.
  • Year by year, Receivables - Net stood at $6.5 billion in 2021, then fell by 4.15% to $6.2 billion in 2022, then grew by 5.58% to $6.6 billion in 2023, then rose by 5.48% to $6.9 billion in 2024, then grew by 14.5% to $7.9 billion in 2025.
  • Business Quant data shows Receivables - Net for ABT at $7.9 billion in Q4 2025, $8.1 billion in Q3 2025, and $8.0 billion in Q2 2025.